These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

214 related items for PubMed ID: 25824903

  • 1. Functional differences between antiviral activities of sulfonated and intact intravenous immunoglobulin preparations toward varicella-zoster virus and cytomegalovirus.
    Yajima M, Shiraki A, Daikoku T, Oyama Y, Yoshida Y, Shiraki K.
    J Infect Chemother; 2015 Jun; 21(6):427-33. PubMed ID: 25824903
    [Abstract] [Full Text] [Related]

  • 2. Interaction of Immunoglobulin with Cytomegalovirus-Infected Cells.
    Aiba N, Shiraki A, Yajima M, Oyama Y, Yoshida Y, Ohno A, Yamada H, Takemoto M, Daikoku T, Shiraki K.
    Viral Immunol; 2017 Sep; 30(7):500-507. PubMed ID: 28598267
    [Abstract] [Full Text] [Related]

  • 3. Cytomegalovirus neutralization by hyperimmune and standard intravenous immunoglobulin preparations.
    Planitzer CB, Saemann MD, Gajek H, Farcet MR, Kreil TR.
    Transplantation; 2011 Aug 15; 92(3):267-70. PubMed ID: 21659947
    [Abstract] [Full Text] [Related]

  • 4. Comparison of cytomegalovirus (CMV)-specific neutralization capacity of hyperimmunoglobulin (HIG) versus standard intravenous immunoglobulin (IVIG) preparations: Impact of CMV IgG normalization.
    Schampera MS, Schweinzer K, Abele H, Kagan KO, Klein R, Rettig I, Jahn G, Hamprecht K.
    J Clin Virol; 2017 May 15; 90():40-45. PubMed ID: 28342316
    [Abstract] [Full Text] [Related]

  • 5. Serology indicates cytomegalovirus infection is associated with varicella-zoster virus reactivation.
    Ogunjimi B, Theeten H, Hens N, Beutels P.
    J Med Virol; 2014 May 15; 86(5):812-9. PubMed ID: 24037981
    [Abstract] [Full Text] [Related]

  • 6. Combined use of complement and anti-immunoglobulin in an enhanced neutralization assay for antibodies to varicella-zoster virus.
    Krah DL, Provost PJ, Ellis RW.
    J Virol Methods; 1995 Jun 15; 53(2-3):176-87. PubMed ID: 7673386
    [Abstract] [Full Text] [Related]

  • 7.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 8. Reconstitution of protective immune responses against cytomegalovirus and varicella zoster virus does not require disease development in pediatric recipients of umbilical cord blood transplantation.
    Merindol N, Salem Fourati I, Brito RM, Grenier AJ, Charrier E, Cordeiro P, Caty M, Mezziani S, Malette B, Duval M, Alfieri C, Ovetchkine P, Le Deist F, Soudeyns H.
    J Immunol; 2012 Nov 15; 189(10):5016-28. PubMed ID: 23034171
    [Abstract] [Full Text] [Related]

  • 9.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 10.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 11. Investigation of varicella-zoster virus-infected cell proteins that elicit antibody production during primary varicella using the immune transfer method.
    Palumbo PE, Arvin AM, Koropchak CM, Wittek AE.
    J Gen Virol; 1984 Dec 15; 65 ( Pt 12)():2141-7. PubMed ID: 6096492
    [Abstract] [Full Text] [Related]

  • 12.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 13.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 14. [Serologic follow-up of cytomegalovirus, herpes simplex and varicella-zoster infections in kidney transplant recipients].
    Merlino C.
    G Batteriol Virol Immunol; 1991 Dec 15; 84(1-12):41-52. PubMed ID: 1668971
    [Abstract] [Full Text] [Related]

  • 15. Relative EBV antibody concentrations and cost of standard IVIG and CMV-IVIG for PTLD prophylaxis in solid organ transplant patients.
    Ramirez-Avila L, Garner OB, Cherry JD.
    Pediatr Transplant; 2014 Sep 15; 18(6):599-601. PubMed ID: 25041939
    [Abstract] [Full Text] [Related]

  • 16.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 17. Pharmacokinetics of viral antibodies after administration of intravenous immunoglobulin in patients with chronic lymphocytic leukaemia or multiple myeloma.
    Thürmann PA, Sonnenburg C, Valentová K, Gregora E, Freischläger F, Lissner R.
    Eur J Clin Pharmacol; 2001 Jun 15; 57(3):235-41. PubMed ID: 11497339
    [Abstract] [Full Text] [Related]

  • 18. Assessment of the presence of cytomegalovirus-neutralizing antibody by a plaque-reduction assay.
    Lewis RB, Matzke DS, Albrecht TB, Pollard RB.
    Rev Infect Dis; 1986 Jun 15; 8 Suppl 4():S434-8. PubMed ID: 3018894
    [Abstract] [Full Text] [Related]

  • 19. Prevalence of herpes simplex types 1 and 2, varicella zoster virus, cytomegalovirus, immunoglobulin G antibodies among female university students in Syria.
    Barah F.
    Saudi Med J; 2012 Sep 15; 33(9):990-4. PubMed ID: 22964811
    [Abstract] [Full Text] [Related]

  • 20. Immunoreactivation of Epstein-Barr virus due to cytomegalovirus primary infection.
    Aalto SM, Linnavuori K, Peltola H, Vuori E, Weissbrich B, Schubert J, Hedman L, Hedman K.
    J Med Virol; 1998 Nov 15; 56(3):186-91. PubMed ID: 9783683
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 11.